Table of Contents
1. Gene Therapy Overview
1.1. History and Evolution of Gene Therapies
1.2. What is Gene Therapy
1.3. Types of Gene Therapy
1.4. Ex vivo and in vivo Approaches of Gene Therapy
1.5. RNAi Therapeutics
1.6. CAR-T Technology based Gene Therapy
1.7. Types of Vectors used for Gene Therapy
1.7.1. Viral
1.7.2. Non-Viral
2. Historical Marketed Gene Therapies [2003-2012]
2.1. Rexin-G (Epeius Biotechnologies Corporation)
2.2. Gendicine (SiBiono GeneTech Co., Ltd)
2.3. Neovasculgen [Human Stem Cells Institute (HSCI))
2.4. Glybera (UniQure Biopharma B.V.)
3. First Countries to get an access to Gene Therapies
3.1. Philippines for Rexin-G [2003]
3.2. China for Gendicine [2003]
3.3. Russia for Neovasculgen [2011]
3.4. Selected European Countries for Glybera [2012]
4. Marketed Gene Therapies [Approved in Recent Years]
4.1. KYMRIAH (tisagenlecleucel)
4.1.1. Therapy Description
4.1.2. Therapy Profile
4.1.2.1. Company
4.1.2.2. Approval Date
4.1.2.3. Mechanism of Action
4.1.2.4. Researched Indication
4.1.2.5. Vector Used
4.1.2.6. Vector Type
4.1.2.7. Technology
4.1.2.8. Others Development Activities
4.1.3. KYMRIAH Revenue Forecasted till 2021
4.2. YESCARTA (axicabtagene ciloleucel)
4.2.1. Therapy Description
4.2.2. Therapy Profile
4.2.2.1. Company
4.2.2.2. Approval Date
4.2.2.3. Mechanism of Action
4.2.2.4. Researched Indication
4.2.2.5. Vector Used
4.2.2.6. Vector Type
4.2.2.7. Technology
4.2.2.8. Others Development Activities
4.2.3. YESCARTA Revenue Forecasted till 2021
4.3. LUXTURNA (voretigene neparvovec-rzyl)
4.3.1. Therapy Description
4.3.2. Therapy Profile
4.3.2.1. Company
4.3.2.2. Approval Date
4.3.2.3. Mechanism of Action
4.3.2.4. Researched Indication
4.3.2.5. Vector Used
4.3.2.6. Vector Type
4.3.2.7. Technology
4.3.2.8. Others Development Activities
4.3.3. LUXTURNA Revenue Forecasted till 2021
4.4. STRIMVELIS
4.4.1. Therapy Description
4.4.2. Therapy Profile
4.4.2.1. Company
4.4.2.2. Approval Date
4.4.2.3. Mechanism of Action
4.4.2.4. Researched Indication
4.4.2.5. Vector Used
4.4.2.6. Vector Type
4.4.2.7. Technology
4.4.2.8. Others Development Activities
4.4.3. STRIMVELIS Revenue Forecasted till 2021
5. Comparison of current Regulatory Status for Gene Therapy Products
5.1. U.S
5.2. Europe
5.3. Japan
6. Emerging Gene Therapies [Phase III]
6.1. Gene Based Therapeutics under Development
6.2. Therapy Description
7. Indication of Focus in Gene Therapy
7.1. Cancer
7.2. Neurodegenerative Disorders
7.3. Lysosomal Storage Disorders (LSDs)
7.4. Ocular Diseases
7.5. Muscle Disorders
7.6. Anemia
7.7. Hemophilia
7.8. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency
8. Leading Companies
8.1. Novartis Pharmaceuticals Corporation
8.2. Kite Pharma, Incorporated
8.3. Spark Therapeutics, Inc
8.4. GlaxoSmithKline
8.5. Adaptimmune
8.6. Bluebird bio
8.7. Celgene
8.8. Shanghai Sunway Biotech
8.9. Shenzhen SiBiono GeneTech
8.10. SynerGene Therapeutics
8.11. Other Companies
9. The Future of Gene Therapy
10. Gene Therapy & Premium Pricing: Debates Intensifies with the approval of First Gene Therapies
11. Global Market Size of Gene Therapies (2016-2021)
11.1. Market Analysis by Marketed Gene Therapies
11.2. Market Analysis by Companies
11.3. Market Analysis by Indications
12. Market Size of Gene Therapies Broken Down by G7 Countries
12.1. United States
12.1.1. Market Size of Gene Therapies in United States (2016-2021)
12.1.2. New Therapies Launch and Sales Analysis (2016-2021)
12.1.3. Sales Analysis by Companies (2016-2021)
12.2. Germany
12.2.1. Market Size of Gene Therapies in Germany (2016-2021)
12.2.2. New Therapies Launch and Sales Analysis (2016-2021)
12.2.3. Sales Analysis by Companies (2016-2021)
12.3. France
12.3.1. Market Size of Gene Therapies in France (2016-2021)
12.3.2. New Therapies Launch and Sales Analysis (2016-2021)
12.3.3. Sales Analysis by Companies (2016-2021)
12.4. Italy
12.4.1. Market Size of Gene Therapies in Italy (2016-2021)
12.4.2. New Therapies Launch and Sales Analysis (2016-2021)
12.4.3. Sales Analysis by Companies (2016-2021)
12.5. Spain
12.5.1. Market Size of Gene Therapies in Spain (2016-2021)
12.5.2. New Therapies Launch and Sales Analysis (2016-2021)
12.5.3. Sales Analysis by Companies (2016-2021)
12.6. United Kingdom
12.6.1. Market Size of Gene Therapies in United Kingdom (2016-2021)
12.6.2. New Therapies Launch and Sales Analysis (2016-2021)
12.6.3. Sales Analysis by Companies (2016-2021)
12.7. Japan
12.7.1. Market Size of Gene Therapies in Japan (2016-2021)
12.7.2. New Therapies Launch and Sales Analysis (2016-2021)
12.7.3. Sales Analysis by Companies (2016-2021)
13. Factors Driving the Market of Gene Therapy
14. Factors Restraining the Market of Gene Therapy
15. About Polaris Market Research
16. Disclaimer
17. Sales Support